PharmaSGP Holding SE
- WKN: A2P4LJ
- ISIN: DE000A2P4LJ5
- Land: Deutschland
Nachricht vom 18.05.2021 | 07:30
PharmaSGP: Expected business development in Q1 2021
DGAP-News: PharmaSGP Holding SE
/ Key word(s): Quarterly / Interim Statement
PharmaSGP: Expected business development in Q1 2021
Gräfelfing, 18 May 2021 - PharmaSGP Holding SE has started its 2021 fiscal year as expected, based on preliminary results. While the first quarter of 2020 was not yet negatively impacted by the Covid-19 pandemic, the first quarter of 2021 reflected area-wide lockdowns in PharmaSGP markets. Accordingly, the company has recorded a reduction in revenues and earnings this year. In light of a market recovery expected in the second half of the year, this performance is in line with the Management Board's planning for the year. At the same time, the Management Board identifies attractive opportunities for non-organic growth in the current market environment.
PharmaSGP's business performance in the first three months of 2021 was significantly characterised by the negative effect of the Covid-19 pandemic on the overall non-prescription drug (OTC) market. The OTC market in Germany, PharmaSGP's home market, registered a year-on-year decrease of -16.5 % in the first 15 weeks of 2021, according to data from consultancy SEMPORA. In line with this overall market trend, revenues in the strategically important "Health Brands" category reduced by 20.1 % to € 11.3 million (previous year: € 14.2 million). Despite the enormous challenges, revenues in foreign markets were stable to positive, in line with PharmaSGP's regional expansion strategy. As expected, the revenue development in the "Beauty Brands" category was weak. In this by the pandemic severely affected category, the decrease in revenues in the first quarter amounted to 59.8 %, to a level of € 1.1 million (previous year: € 2.5 million). As PharmaSGP expected, Group revenues consequently reduced by a total of 26.2 % to € 12.4 million in the first quarter of 2021 (previous year: € 16.7 million). Owing to the lower revenue level, earnings before interest and taxes (adjusted EBIT), adjusted for one-time costs and special effects, amounted to € 2.0 million (previous year: € 4.4 million). This corresponds to an adjusted EBIT margin (measured against revenues) of 15.9 % (previous year 26.2 %). Unadjusted EBIT amounted to EUR 1.6 million.
"In the first quarter of 2021, our target markets continued to be impacted by area-wide lockdowns. Firstly, this led to less customers in pharmacies overall. Secondly, we suspended new product launches in light of this situation," notes CEO Natalie Weigand, commenting on the year-on-year trend. She is convinced of the business model's prospects for success, despite the challenges posed by Covid-19: "We combine a scalable asset-light business model with our specialised D2C marketing strategy and high target group reach. However, the platform continues to offer us strategic growth opportunities in such extraordinary times as we are currently experiencing. For this reason, in addition to the organic expansion of our existing 'Health Brands', we are currently focusing on the acquisition and integration of established brands offering value creation potential."
"Our platform enables us to maximise a product's potential," continues Michael Rudolf, CFO of PharmaSGP. "Firstly, by boosting sales through our effective D2C marketing. Secondly, we can achieve cost optimizations by integrating them into our efficient business model. By growing sales and optimizing margins we are creating added value for PharmaSGP and its owners."
The further course of the Covid-19 pandemic represents a key factor for the overall development of PharmaSGP in 2021. With a look to relevant European OTC markets, PharmaSGP expects year-on-year growth to occur in the second half of the year at the earliest, assuming no renewed negative impact on PharmaSGP's relevant OTC markets in Europe in the second half of 2021. For the 2021 fiscal year, the Management Board continues to anticipate revenues of between € 56 million and € 60 million, with a stable to slightly positive trend in the "Health Brands" category, and a decrease in the "Beauty Brands" business, as expected. The adjusted EBIT margin is anticipated to rise to between 27 % and 30 % compared to the 2020 fiscal year. Potential acquisitions are not included in the forecast.
PharmaSGP will publish the full first quarter 2021 announcement on
OVERVIEW OF PRELIMINARY YEAR-ON-YEAR FINANCIALS
One-time costs and special effects amounted to € 0.4 million in Q1 2021 and € 0.1 million in Q1 2020 and include, among other items, costs for the corporate and organizational structuring of the PharmaSGP Group, as well as legal and consulting fees in connection with planned acquisitions.
ABOUT PHARMASGP HOLDING SE
PharmaSGP is a leading consumer health company focusing on non-prescription pharmaceuticals sold over the counter ("OTC"). PharmaSGP's products are sold exclusively through pharmacies. Its products are based on natural active pharmaceutical ingredients with documented efficacy and fewer known side effects than most chemical-based pharmaceuticals.
The Company's core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX(R) for rheumatic pain and Restaxil(R) for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France.
PharmaSGP generated revenues of € 63.2 million at an EBIT margin of 26.1 % in 2020.
In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP's product offering, leverage established brand families to introduce new chemical-free OTC and other healthcare products, increase PharmaSGP's European footprint, and accelerate its growth strategy especially by capitalizing on selected M&A opportunities.
|Company:||PharmaSGP Holding SE|
|Lochhamer Schlag 21|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich|
|EQS News ID:||1197477|
|End of News||DGAP News Service|
Event im Fokus
10. Juni 2021:Fachkonferenz Immobilien
14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure
13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie
10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix
„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“
Cryptology Asset Group PLC: 120 % Kurspotenzial
GBC Research hat mit der Coverage der Cryptology Asset Group PLC (ISIN: MT0001770107) begonnen. Die Bewertung der führenden europäischen Investmentgesellschaft für Krypto-Assets und Blockchain-Unternehmen erfolgte mittels der Berechnung des Net Asset Value (NAV). Unter Berücksichtigung aller Beteiligungen ergibt sich zum 05. Juli 2021 eine GBC-Fair-NAV-Bewertung in Höhe von 1,04 Mrd. EUR. Daraus ergibt sich ein NAV je Cryptology-Aktie von 358,43 EUR. Daher empfiehlt GBC Research die Cryptology-Aktie zum Kauf und sieht ein Kurspotenzial von über 120 %.
Der AKTIONÄR News
01. August 10:50 Traeger: Gelungener Börsengang und starke Aussichten
01. August 10:49 Das größte Geheimnis von Warren Buffett
01. August 07:22 DAX-Wochenausblick: Neuer Schwung dank Zahlen-Flut?
01. August 07:00 Recovery Index: Capri präsentiert echte Luxus-Zahlen
01. August 06:00 Bitcoin-Boom: Erst top, dann Flop – wie geht der Hype nun weiter?
News im Fokus
Vonovia SE: Job mit Zukunft: Rund 200 Auszubildende starten ihre Karriere bei Vonovia (News mit Zusatzmaterial)
30. Juli 2021, 12:28
Registrierung zum H1 2021 Trading Update der AUTO1 Group SE am 6. August um 15:30 Uhr MESZ
06. August 2021
Original-Research: Vectron Systems AG (von GBC AG): Buy
30. Juli 2021